Morovir — Molnupiravir 200 mg Capsules, 40 Caps

Morovir 200 mg is supplied in the form of hard gelatin capsules for oral administration. The capsules feature an opaque cap and body to protect the contents from photo-degradation caused by light exposure.

Qualitative and Quantitative Composition per Capsule:

• • Active Ingredient: Molnupiravir I.P. — 200 mg.
• • Capsule Core Excipients: Microcrystalline cellulose (filler), croscarmellose sodium (disintegrant), magnesium stearate (lubricant), colloidal silicon dioxide.
• • Capsule Shell Composition: Gelatin, Titanium Dioxide I.P. (colorant and opacifier), purified water.

Packaging Configuration: 200 mg capsules are packed in lots of 40 pieces into polymer bottles with protective closure or into blister packs. The package contains exactly 40 capsules — a quantity precisely calculated for 1 full 5-day course of therapy (4 capsules twice daily). The bottle/blisters are packed in a Bruck cardboard carton together with official prescribing instructions.

Pharmacodynamics and Molecular Action:
Molnupiravir is an isopropyl ester prodrug of the synthetic nucleoside derivative N4-hydroxycytidine (NHC). Following oral absorption, molnupiravir undergoes rapid systemic hydrolysis into NHC. Intracellularly, NHC is phosphorylated by cellular kinases into active NHC-triphosphate (NHC-TP).

Incorporation of NHC-TP into viral RNA by the viral RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2 occurs without chain termination. However, when viral polymerase uses this modified RNA as a template, NHC-TP is recognized with equal frequency as either cytidine or uridine. This leads to widespread transition errors (G->A and C->U) during subsequent replication cycles. Accumulation of a catastrophic number of mutations across the viral genome renders the virus incapable of replication (viral error catastrophe).

Pharmacokinetics:

• • Absorption: Rapidly absorbed after oral administration. Peak plasma concentration ($T_{max}$) of molnupiravir occurs in 0.5–1.0 hour, while active metabolite NHC reaches $T_{max}$ at 1.5 hours. Co-administration with food has no clinically relevant effect on total NHC exposure (AUC).
• • Distribution: NHC exhibits 0% human plasma protein binding. The volume of distribution is approximately 142 L, indicating extensive tissue penetration into respiratory tract organs.
• • Metabolism: Molnupiravir and NHC are metabolized via endogenous pyrimidine pathways to uridine and cytidine, without involvement of the cytochrome P450 enzyme system.
• • Elimination: Plasma half-life ($T_{1/2}$) of molnupiravir is ~1 hour, and NHC is ~3.3 hours. Renal excretion accounts for less than 3% of the dose; primary clearance occurs via metabolic processing.

Pharmacodynamics and Molecular Action:
Molnupiravir is an isopropyl ester prodrug of the synthetic nucleoside derivative N4-hydroxycytidine (NHC). Following oral absorption, molnupiravir undergoes rapid systemic hydrolysis into NHC. Intracellularly, NHC is phosphorylated by cellular kinases into active NHC-triphosphate (NHC-TP).

Incorporation of NHC-TP into viral RNA by the viral RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2 occurs without chain termination. However, when viral polymerase uses this modified RNA as a template, NHC-TP is recognized with equal frequency as either cytidine or uridine. This leads to widespread transition errors (G->A and C->U) during subsequent replication cycles. Accumulation of a catastrophic number of mutations across the viral genome renders the virus incapable of replication (viral error catastrophe).

Pharmacokinetics:

• • Absorption: Rapidly absorbed after oral administration. Peak plasma concentration ($T_{max}$) of molnupiravir occurs in 0.5–1.0 hour, while active metabolite NHC reaches $T_{max}$ at 1.5 hours. Co-administration with food has no clinically relevant effect on total NHC exposure (AUC).
• • Distribution: NHC exhibits 0% human plasma protein binding. The volume of distribution is approximately 142 L, indicating extensive tissue penetration into respiratory tract organs.
• • Metabolism: Molnupiravir and NHC are metabolized via endogenous pyrimidine pathways to uridine and cytidine, without involvement of the cytochrome P450 enzyme system.
• • Elimination: Plasma half-life ($T_{1/2}$) of molnupiravir is ~1 hour, and NHC is ~3.3 hours. Renal excretion accounts for less than 3% of the dose; primary clearance occurs via metabolic processing.

Therapy with Morovir 200 mg must be prescribed by a licensed healthcare professional following confirmed diagnosis of COVID-19.

Method of Administration:
For oral use. Capsules must be swallowed whole with a sufficient volume of water (100–200 mL). Do not open, crush, or chew the capsules, as this may alter active ingredient stability and bioabsorption.

Food Effect:
May be taken with or without food (on an empty stomach or with meals).

Standard Dosage Regimen:

• • Adults (≥18 years): Recommended dose is 800 mg (4 capsules of 200 mg) every 12 hours (twice daily) for 5 days. Single dose — 4 capsules; total daily dose — 8 capsules (1600 mg).
• • Duration of Treatment: Exactly 5 consecutive days. Total course dose is 40 capsules (exactly 1 pack of Morovir). Extending treatment beyond 5 days is not recommended.

Missed Dose Instructions:

• • If missed by less than 10 hours: Take the missed dose (4 capsules) immediately, then resume normal dosing schedule.
• • If missed by more than 10 hours: Skip the missed dose and take the next dose at the regularly scheduled time. Do not take a double dose to compensate.

Special Populations:

• • Renal / Hepatic Impairment: No dosage adjustment is required in patients with any degree of renal or hepatic impairment.
• • Elderly (≥65 years): No dosage adjustment required.

Administration of Morovir 200 mg is strictly contraindicated in the following cases:

• • Hypersensitivity: Hypersensitivity to molnupiravir or any excipient contained in the capsule shell or core.
• • Pregnancy and Conception Planning: Contraindicated in pregnant women due to potential embryofetal toxicity and teratogenic risk.
• • Lactation: Breastfeeding is contraindicated during treatment and for 4 days after the final dose.
• • Age Limits: Children and adolescents under 18 years of age (due to potential risk to bone and cartilage growth).
• • Males Planning Conception: Sexually active men with partners of childbearing potential must use reliable contraception during treatment and for 3 months after the final dose of Morovir.

Based on available clinical and in vitro study data, no significant drug interactions have been identified for molnupiravir.

Interaction Characteristics:

• • Cytochrome P450 System: Molnupiravir and its active metabolite NHC are not inhibitors or inducers of CYP450 enzymes (CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4). No altered efficacy of co-administered hepatic-metabolized drugs is expected.
• • Drug Transporters: NHC is not a substrate or inhibitor of major transporters (P-gp, BCRP, OATP1B1, OATP1B3, OCT2, MATE1, MATE2K).
• • Concomitant COVID-19 Medications: Can be safely combined with antipyretics (paracetamol, NSAIDs), anticoagulants, systemic corticosteroids, and monoclonal antibodies. No antagonism with other antiviral drugs was observed.

Pregnancy:
Use of Morovir during pregnancy is strictly contraindicated. Animal preclinical studies showed teratogenicity, embryo-fetal lethality, and malformations at clinical exposure levels.

Females of reproductive potential should undergo pregnancy testing before initiating treatment. Reliable contraception must be maintained during treatment and for 4 days after the last dose of Morovir.

Lactation:
Excretion of molnupiravir or NHC in human milk is unknown. Due to potential serious adverse reactions in nursing infants, breastfeeding must be discontinued during the 5-day treatment course and for at least 4 days after the final capsule intake.

Morovir 200 mg exhibits a favorable safety and tolerability profile. Reported adverse events are predominantly mild-to-moderate in severity and resolve spontaneously upon completion of the course.

Adverse Reaction Frequency:

• • Gastrointestinal Disorders: Common (≥1/100, <1/10) — diarrhea, nausea; Uncommon (≥1/1000, <1/100) — vomiting, abdominal pain, dyspepsia, flatulence.
• • Nervous System Disorders: Common — dizziness, headache; Uncommon — somnolence.
• • Skin and Subcutaneous Tissue Disorders: Uncommon — rash, urticaria, pruritus.
• • Laboratory Parameters: Rare — transient, mild elevation of ALT, AST, or serum creatinine levels.

Symptoms:
Human data on acute molnupiravir overdose is limited. Accidental massive overdose may lead to exacerbation of known side effects, primarily gastrointestinal symptoms (severe nausea, vomiting, diarrhea) and central nervous system effects (marked dizziness).

Treatment:
There is no specific antidote. In case of overdose, gastric lavage, administration of oral adsorbents (activated charcoal), and general supportive therapy are recommended. Due to low plasma protein binding of NHC, hemodialysis may potentially facilitate clearance.

Storage Requirements for Morovir 200 mg:

• 🌡️ Temperature: Store at temperatures below 30°C (Store below 30°C) in a dry place. Do not freeze.
• ☀️ Light and Moisture Protection: Keep in original packaging to protect from direct sunlight and moisture (Protect from light & moisture).
• 👶 Safety: Keep out of reach of children (Keep out of reach of children).
• ⏳ Shelf Life: 24 months from date of manufacture. Do not use after expiration date. Prescription status: Prescription only (Rx-only / CAUTION: Not to be sold by retail without the prescription of a Registered Medical Practitioner).

To protect consumers from counterfeit products, Bruck Pharma employs explicit security features on Morovir 200 mg packaging:

• ✅ Brand Logo: Prominent red geometric logo and "Bruck" wordmark in burgundy clear typography on the front panel.
• ✅ Color & Design Elements: Characteristic double vertical green bar on the left and bold dark-green "MOROVIR" product name printing/foil stamping.
• ✅ Clear Composition Labeling: Side panel specifies "Molnupiravir I.P. 200 mg" and shell dye "Titanium Dioxide I.P.".
• ✅ Red Caution Box: Lower left front corner includes a mandatory red rectangular box with official prescription caution text (CAUTION).
• ✅ Batch Information: Embossed or printed Batch No., Mfg Date, and Exp Date on the carton flap or bottom.